SECURITIES AND EXCHANGE COMMISSION

                              Washington, DC 20549

                                   FORM 10Q-SB


                  Quarterly Report under Section 13 or 15(d) of
                       the Securities Exchange Act of 1934


For Quarter Ended                                         Commission File Number
-----------------                                         ----------------------
June 30, 2002                                                          000-26907


                        BIO-AMERICAN CAPITAL CORPORATION
                      ------------------------------------
             (Exact name of registrant as specified in its charter)


Nevada                                                               93-1118938
------                                                               ----------
(State of incorporation)                                 IRS Employer ID Number


462 Stevens Avenue, Suite #308, Solana Beach, CA                           92075
(Address of principal executive offices)                              (Zip Code)


                                  858.793.5900
                         (Registrant's Telephone number)


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to the filing
requirements for at least the past 90 days.

                       Yes   X          No
                           -----           -----

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.

                   3,930,250 common shares as of June 30, 2002



<PAGE>


                                TABLE OF CONTENTS



                         PART I - FINANCIAL INFORMATION

                                                                            Page

Item 1    Financial Statements.........................................F-1 - F-5

Item 2    Management Discussion and Analysis of Financial Condition and
          Results of Operations................................................9



                   PART II - OTHER INFORMATION

Item 1    Legal Proceedings...................................................10

Item 2    Changes in Securities...............................................10

Item 3    Default Upon Senior Securities......................................10

Item 4    Submission of Matters to a Vote of Security Holders.................10

Item 5    Other Information...................................................10

Item 6    Exhibits and Reports on Form 8-K....................................10



                            PART III

          Signature                                                           11



<PAGE>


                         PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements.
-----------------------------

         For financial information, please see the financial statements and the
notes thereto, attached hereto and incorporated by this reference.

         The financial statements have been prepared by Bio-American Capital
Corporation without audit pursuant to the rules and regulations of the
Securities and Exchange Commission. Certain information and footnotes
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted as
allowed by such rules and regulations, and management believes that the
disclosures are adequate to make the information presented not misleading. These
financial statements include all the adjustments which, in the opinion of
management, are necessary to a fair presentation of financial position and
results of operations. All such adjustments are of a normal and recurring
nature. These financial statements should be read in conjunction with the
audited financial statements at December 31, 2001, included in the Company's
Form 10-SB.




<PAGE>


                        BIO-AMERICAN CAPITAL CORPORATION

                              Financial Statements
                  For the Six Month Period Ended June 30, 2002
                                   (Unaudited)


<PAGE>



                                Michael Johnson
                             9175 Kenyon Ave., #100
                                Denver, CO 80237
                              Phone: 303-796-0099
                               Fax: 303-796-0137




           REPORT ON REVIEW BY INDEPENDENT CERTIFIED PUBLIC ACCOUNTANT


To the Board of Directors
Bio-American Capital Corporation


We have reviewed the accompanying balance sheet of Bio-American Capital
Corporation as of June 30, 2002 and the related statements of operations and
cash flows for the six months ended June 30, 2002 and 2001 included in the
accompanying Securities and Exchange Commission Form 10-QSB for the period ended
June 30, 2002. These financial statements are the responsibility of the
Company's management.

We conducted our reviews in accordance with standards established by the
American Institute of Certified Public Accountants. A review of interim
financial information consists principally of applying analytical procedures to
financial data and making inquiries of persons responsible for financial and
accounting matters. It is substantially less in scope than an audit conducted in
accordance with auditing standards generally accepted in the United States, the
objective of which is the expression of an opinion regarding the financial
statements as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should
be made to the accompanying financial statements for them to be in conformity
with accounting principles generally accepted in the United States.

We have previously audited, in accordance with auditing standards generally
accepted in the United States, the balance sheet as of December 31, 2001, and
the related statements of operations, stockholders' equity and cash flows for
the year then ended (not presented herein). In our report dated March 16, 2002,
we expressed an unqualified opinion on those financial statements. In our
opinion, the information set forth in the accompanying balance sheet as of June
30, 2002 is fairly stated in all material respects in relation to the balance
sheet from which it has been derived.


/s/ Michael Johnson & Co., LLC.
Michael Johnson & Co., LLC.
Denver, Colorado
August 16, 2002


                                      F-1

<PAGE>

<TABLE>
<CAPTION>


                               BIO-AMERICAN CAPITAL CORP.
                             (A Development Stage Company)
                                     Balance Sheet


                                                                             June 30,            December 31,
                                                                               2002                  2001
                                                                           --------------      -----------------
                                                                            (Unaudited)
<S>                                                                        <C>                 <C>

ASSETS:

Current Assets:
     Cash                                                                           $ 95                   $ 99
                                                                           --------------      -----------------

TOTAL ASSETS                                                                        $ 95                   $ 99
                                                                           ==============      =================


LIABILITIES & STOCKHOLDERS' DEFICIT:

Current Liabilities:
  Accounts Payable                                                               216,248                180,773
  Accrued Liabilities                                                              6,550                  3,100

                                                                           --------------      -----------------
Total Current Liabilities                                                        222,798                183,873
                                                                           --------------      -----------------

Stockholders' Deficit:
     Common Stock, par value $0.001; 100,000,000
       shares authorized; 3,930,250 shares issued and
       outstanding in 2001 and 2000 respectively                                   3,930                  3,930
   Additional Paid-in Capital                                                    543,083                543,083
   Accumulated Deficit during the Development Stage                             (769,716)              (730,787)
                                                                           --------------      -----------------

                                                                           --------------      -----------------
Total Stockholders' Deficit                                                     (222,703)              (183,774)
                                                                           --------------      -----------------

TOTAL LIABILITIES & STOCKHOLDERS' DEFICIT                                           $ 95                   $ 99
                                                                           ==============      =================
</TABLE>


   The accompanying notes are an integral part of these finacial statements.

                                      F-2

<PAGE>

<TABLE>
<CAPTION>


                                BIO-AMERICAN CAPITAL CORP.
                              (A Development Stage Company)
                                 Statements of Operations

                                       (Unaudited)

                                                                                                                 For the
                                                                                                                  Period
                                                                                                                May 5, 1992
                                                     Three Months Ended               Six Months Ended          (Inception) to
                                                          June 30,                        June 30,               June 30,
                                               -------------------------------    --------------------------
                                                     2002             2001           2002              2001        2002
                                               -----------------    ----------    -----------    -----------    -----------
<S>                                            <C>                  <C>           <C>            <C>            <C>
REVENUE:                                                    $ -           $ -            $ -            $ -            $ -

EXPENSES:
   Provision for Bad Debt                                     -             -              -              -        453,432
   Amortization                                               -             -              -              -            500
   Professional Expenses                                  1,620         4,940          3,115          4,940         60,637
   Management Fees                                       15,000        15,000         30,000         30,000        220,000
   Other                                                    478            30          1,314             60          3,689
   Office Expenses                                        2,250         2,250          4,500          4,500         33,000
                                               -----------------    ----------    -----------    -----------    -----------
Total Expenses                                           19,348        22,220         38,929         39,500        771,258

OTHER INCOME/EXPENSES
   Interest Income                                                                                                   3,372
   Other Expenses                                             -             -              -              -         (1,830)
                                               -----------------    ----------    -----------    -----------    -----------
Total Other Income/Expenses                                   -             -              -              -          1,542

NET LOSS                                              $ (19,348)    $ (22,220)     $ (38,929)     $ (39,500)      (769,716)
                                               =================    ==========    ===========    ===========    ===========

Net Loss Per Share                                          $ -       $ (0.01)       $ (0.01)       $ (0.01)
                                               =================    ==========    ===========    ===========

Weighted Average Shares Outstanding                   3,930,250     3,930,250      3,930,250      3,930,250
                                               =================    ==========    ===========    ===========
</TABLE>

   The accompanying notes are an integral part of these finacial statements.

                                      F-3

<PAGE>

<TABLE>
<CAPTION>


                                   BIO-AMERICAN CAPITAL CORP.
                                 (A Development Stage Company)
                                    Statements of Cash Flows

                                          (Unaudited)

                                        Indirect Method


                                                                                                                 For the
                                                                                                                  Period
                                                                                                                May 5, 1992
                                                       Three Months Ended          Six Months Ended             (Inception) to
                                                            June 30,                   June 30,                  June 30,
                                                     -----------------------   -------------------------
                                                       2002         2001          2002          2001               2002
                                                     ----------   ----------   -----------    ----------        -----------
<S>                                                  <C>          <C>          <C>            <C>               <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss                                             $ (19,348)    $(22,220)    $ (38,929)    $ (39,500)        $ (769,716)
Adjustments to reconcile net loss to net cash
  used in operating activities;
   Amortization                                              -            -             -             -                500
  Stock issued for accrued liabilities                       -            -             -             -                  -
  Changes in assets and liabilities:
     Increase (Decrease) in Accounts Payable            17,930       22,000        35,475        39,250            216,248
     Increase (Decrease)  in Accrued Liabilities         1,450          150         3,450           250              6,550
                                                     ----------   ----------   -----------    ----------        -----------
                                                        19,380       22,150        38,925        39,500            222,798
                                                     ----------   ----------   -----------    ----------        -----------
Net Cash Used in Operating Activities                       32          (70)           (4)            0           (546,418)

CASH FLOWS FROM INVESTING ACTIVITIES:
     Incorporation Costs                                     -            -             -             -               (500)
                                                     ----------   ----------   -----------    ----------        -----------
Net Cash Used in Investing Activities                        -            -             -             -               (500)

CASH FLOWS FROM FINANCING ACTIVITIES:
    Proceeds from Sale of Common Stock                       -            -             -             -            505,013
    Proceeds from Notes Payable                              -            -             -             -             16,500
                                                     ----------   ----------   -----------    ----------        -----------
Net Cash Provided by Financing Activities                    -            -             -             -            521,513
                                                     ----------   ----------   -----------    ----------        -----------

(Decrease) Increase in Cash                                 32          (70)           (4)            -            (25,405)

Cash - Beginning of Period                                  63           97            99            27                  -
                                                     ----------   ----------   -----------    ----------        -----------

Cash - End of Period                                      $ 95         $ 27          $ 95          $ 27          $ (25,405)
                                                     ==========   ==========   ===========    ==========        ===========

Supplemental Disclosures
       Interest                                            $ -          $ -           $ -         $ 744            $ 1,830
                                                     ==========   ==========   ===========    ==========        ===========
       Income taxes                                        $ -          $ -           $ -           $ -                $ -
                                                     ==========   ==========   ===========    ==========        ===========


Noncash investing and financing activities:
Issuance of common stock in exchange for
cancellation of note payable of $16,500 and
accrued expenses of $25,000
                                                     ----------   ----------   -----------    ----------        -----------
                                                           $ -          $ -           $ -           $ -           $ 42,000
                                                     ==========   ==========   ===========    ==========        ===========
</TABLE>


   The accompanying notes are an integral part of these financial statements.

                                      F-4


<PAGE>




                        BIO-AMERICAN CAPITAL CORPORATION
                          (A Development Stage Company)
                          Notes to Financial Statements
                                  June 30, 2002
                                   (Unaudited)


1.       Presentation of Interim Information

         In the opinion of the management of Bio-American Capital Corporation,
the accompanying unaudited financial statements include all normal adjustments
considered necessary to present fairly the financial position as of June 30,
2002, and the results of operations and cash flows for the three months and six
months ended June 30, 2002 and 2001. Interim results are not necessarily
indicative of results for a full year.

     The financial statements and notes are presented as permitted by Form
10-QSB, and do not contain certain information included in the Company's audited
financial statements and notes for the fiscal year ended December 31, 2001.


                                      F-5


<PAGE>


Item 2.  Management's Discussion and Analysis of Financial Condition and Result
-------------------------------------------------------------------------------
of Operations
-------------

Results of Operations

         The Company had no revenue or operations for the period. There can be
no assurance that the Company will be able to complete a merger with an
operating company. Due to the lack of a specified business opportunity, the
Company is unable to predict the period for which it can conduct operations.

Comparison of Operating Results for the Three Months Ended June 30, 2002 and
June 30, 2001

         The Company had no revenues for the three months ended June 30, 2002
and June 30, 2001. In 2002 the Company incurred $19,348 in expenses compared to
$22,220 in 2001. The $19,348 of expenses in 2002 included: $15,000 as a
management fee to the former President of the Company; $2,250 for office and
related expenses; and $1,500 for legal services. The $22,220 of expenses in 2001
included: $15,000 as a management fee to the former President of the Company;
$2,250 for office and related expenses; $2,900 for legal services and $1,850 for
financial coverage.

         The net operating loss in the second quarter in 2002 was $19,348 as
compared to $22,220 in 2001. The net loss per share for the quarter each year
was less than $0.01 in 2002 and $0.01 in 2001.

Comparison of Operating Results for the Six Months Ended June 30, 2002 and June
-------------------------------------------------------------------------------
30, 2001
--------

         The Company had no revenues for the six months ended June 30, 2002 and
June 30, 2001. In 2002 the Company incurred $38,929 in expenses compared to
$39,500 in 2001. The $38,929 of expenses in 2002 included: $30,000 as a
management fee to the former President of the Company; $4,500 for office and
related expenses; and $4,500 for legal services. The $39,500 of expenses in 2001
included: $30,000 as a management fee to the former President of the Company;
$4,500 for office and related expenses; $2,900 for legal services and $1,850 was
incurred for financial coverage.

         The net operating loss in the six months ended June 30, 2002 was
$38,929 as compared to $39,500 in 2001. The net loss per share for the six
months ended June 30, 2002 and June 30, 2001 was $0.01.

         For the current fiscal year, the Company anticipates incurring a loss
as a result of the management fee to the President of the Company, office and
related expenses, expenses associated with regulatory filings, and expenses
associated with locating and evaluating acquisition candidates. The Company
anticipates that until a business combination is completed with an acquisition
candidate, it will not generate revenues, and may continue to operate at a loss
after completing a business combination, depending upon the performance of the
acquired business.


<PAGE>

Liquidity and Capital Resources
-------------------------------

         At June 30, 2002, the Company had no cash or other assets with which to
conduct operations. The lack of liquidity or liquid assets raises substantial
doubt about the Company's ability to continue as a going concern unless it is
able to generate sufficient cash flows to meet its obligations and sustain
operations. To meet required current operating expenses the Company is totally
dependent upon its principal shareholder to advance funds until the Company has
acquired another entity that has sufficient resources to fund the Company's
operations. The Company's primary ongoing monthly cost include a $5,000
management fee, $750 for an office and related expenses, and cost associated
with regulatory filings. The payments for these expenses have been deferred
until sufficient cash is available.

         Once the Company has identified an appropriate business combination,
lack of existing capital may be a sufficient impediment to prevent its
consummation. And if a business combination is completed, the Company's needs
for additional financing is likely to increase substantially.



<PAGE>


                          PART II - OTHER INFORMATION

Item 1.  Legal Proceedings.
---------------------------

         The Company is not a party to any pending legal proceedings, and no
such proceedings are known to be contemplated.


Item 2.  Change in Securities.
------------------------------

         (a) There have been no material modifications in any of the instruments
defining the rights of the holders of any of the Company's registered
securities.

         (b) None of the rights evidenced by any class of the Company's
registered securities have been materially limited or qualified by the issuance
or modification of any other class of the Company's securities.


Item 3.  Defaults Upon Senior Securities.
-----------------------------------------

         (Not applicable)


Item 4.  Submission of Matters to a Vote of Security Holders.
-------------------------------------------------------------

         (Not applicable)


Item 5.  Other Information.
---------------------------

         (Not applicable)


Item 6.  Exhibits and Reports on Form 8-K.
------------------------------------------

(a)      Exhibits

         No exhibits as set forth in Regulation SB, are considered necessary for
this filing.

(b)      Reports on Form 8-K

         No reports on Form 8-K were filed during the quarter for which this
report is filed.




<PAGE>


                                   SIGNATURES

         In accordance with the requirements of the Securities and Exchange Act
of 1934, as amended, the registrant caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.


                                            Bio-American Capital Corporation

                                            By: /s/ Donald L. Walker
Date:  August 19, 2002                          ------------------------------
                                                Donald L. Walker, President